Document is current

Article History

Received: 11 July 2024

Accepted: 15 October 2024

First Online: 12 November 2024

Declarations

:

: MB reports grants from Becton Dickinson; consulting fees from Becton Dickinson and Edwards LifesSciences; honoraria for lectures from Becton Dickinson; and payment for participation on an advisory board for Becton Dickinson and Edwards LifesSciences. BR reports grants from Aguettant and i-SEP; consulting fees from LFB, Aguettant and Nordic Pharma; and attending meetings or travel from i-SEP. JFT reports grants from MSD and Pfizer; honoraria for lectures from Becton Dickinson and Shionogi; and payment for participation on an advisory board for MSD, Pfizer, Gilead, Advanz, Roche and Becton Dickinson. OM reports grants from 3 M and Becton Dickinson; consulting fees from 3 M and Becton Dickinson; honoraria for lectures from 3 M and Becton Dickinson; support for attending meetings or travel from 3 M and Becton Dickinson; and payment for participation on an advisory board for 3 M and Becton Dickinson. All other authors declare no competing interests.

: The funders had no role in the design or execution of the trial, data analysis, or writing or reviewing of the manuscript.

: Data collected for the study, including participant data, the data dictionary defining each field in the set, and the study protocol, will be made available to others. Data will be communicated as de-identified participant data according to French law, and will be available after publication of the manuscript. Data will be made available at the Direction de la Recherche, Poitiers University Hospital, Poitiers, France (drci@chu-poitiers.fr), with investigator support, after approval of a proposal with a signed data access agreement.